These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35452792)

  • 21. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
    Peters SA; Ungell AL; Dolgos H
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of physiologically based absorption and pharmacokinetic modeling in the development process of oral modified release generic products.
    Subhani S; Kim C; Muniz P; Rodriguez M; van Os S; Suarez E; Cristofoletti R; Schmidt S; Vozmediano V
    Eur J Pharm Biopharm; 2022 Jul; 176():87-94. PubMed ID: 35598768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toward Greater Insights on Applications of Modeling and Simulation in Pregnancy.
    Song L; Cui C; Zhou Y; Dong Z; Yu Z; Xu Y; Zhou T; Abduljalil K; Han H; Li L; Yang J; Zhao Y; Li H; Liu D
    Curr Drug Metab; 2020; 21(9):722-741. PubMed ID: 32895038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Crosstalk of physiological pH and chemical pKa under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity.
    Gaohua L; Miao X; Dou L
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1103-1124. PubMed ID: 34253134
    [No Abstract]   [Full Text] [Related]  

  • 26. Coupling biorelevant dissolution methods with physiologically based pharmacokinetic modelling to forecast in-vivo performance of solid oral dosage forms.
    Otsuka K; Shono Y; Dressman J
    J Pharm Pharmacol; 2013 Jul; 65(7):937-52. PubMed ID: 23738721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling.
    Moss DM; Siccardi M
    Br J Pharmacol; 2014 Sep; 171(17):3963-79. PubMed ID: 24467481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specificity of pharmacokinetic modeling of nanomedicines.
    Lebreton V; Legeay S; Saulnier P; Lagarce F
    Drug Discov Today; 2021 Oct; 26(10):2259-2268. PubMed ID: 33892140
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
    Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
    Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches.
    Guo Y; Chu X; Parrott NJ; Brouwer KLR; Hsu V; Nagar S; Matsson P; Sharma P; Snoeys J; Sugiyama Y; Tatosian D; Unadkat JD; Huang SM; Galetin A;
    Clin Pharmacol Ther; 2018 Nov; 104(5):865-889. PubMed ID: 30059145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
    Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Progress in methodology of establishing physiologically based pharmacokinetic models].
    Jin YW; Ma YM
    Yao Xue Xue Bao; 2014 Jan; 49(1):16-22. PubMed ID: 24783500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically based pharmacokinetic (PBPK) modeling in children.
    Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
    Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-Drug Interaction Between Oxycodone and Diazepam by a Combined
    Ji B; Xue Y; Xu Y; Liu S; Gough AH; Xie XQ; Wang J
    ACS Chem Neurosci; 2021 May; 12(10):1777-1790. PubMed ID: 33950681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.